DT&CRO CO., Ltd. (KOSDAQ:383930)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,565.00
-30.00 (-0.83%)
At close: Apr 28, 2026
-37.35%
Market Cap 45.58B
Revenue (ttm) 47.75B
Net Income (ttm) -2.78B
Shares Out 12.78M
EPS (ttm) -217.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 141,695
Average Volume 173,417
Open 3,550.00
Previous Close 3,595.00
Day's Range 3,470.00 - 3,645.00
52-Week Range 2,250.00 - 6,550.00
Beta 1.50
RSI 55.32
Earnings Date n/a

About DT&CRO CO.

DT&CRO CO., Ltd. operates as a full-service CRO provider in South Korea. The company conducts a series of consigned studies ranging from non-clinical GLP toxicity, PK, and efficacy tests required for licensing of pharmaceuticals, chemicals, health functional food, cosmetics, and medical devices to analysis, bioactivity, clinical trials, and licensing consulting. DT&CRO CO., Ltd. was founded in 2017 and is based in Yongin-si, South Korea. [Read more]

Industry Commercial Physical and Biological Research
Founded 2017
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 383930
Full Company Profile

Financial Performance

In 2025, DT&CRO CO.'s revenue was 47.75 billion, an increase of 32.74% compared to the previous year's 35.97 billion. Losses were -2.78 billion, 38.9% more than in 2024.

Financial Statements

News

There is no news available yet.